All Stories

  1. Older Brothers and Male Homosexuality: Antibodies as an Explanation
  2. Ketamine as anaesthesia for ECT: is there room to improve a gold standard treatment?
  3. Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem
  4. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: Systematic review and meta-analysis of randomized controlled trials
  5. A simple rearrangement can improve visual understanding of a Forest plot
  6. Theoretical and practical issues related to the management of severe and refractory psychotic illness complicated by pulmonary embolism
  7. A Critical Examination of Studies on Curcumin for Depression
  8. Antidepressant Augmentation With Anti-Inflammatory Agents
  9. Images in Electroconvulsive Therapy
  10. Images in Electroconvulsive Therapy
  11. Cause Versus Association in Observational Studies in Psychopharmacology
  12. Musical obsessions: A comprehensive review of neglected clinical phenomena
  13. Nonsteroidal Anti-inflammatory Drugs and 5-HT 3 Serotonin Receptor Antagonists as Innovative Antipsychotic Augmentation Treatments for Schizophrenia
  14. A Primer for the Conceptualization of the Mechanism of Action of Electroconvulsive Therapy, 2: Organizing the Information
  15. Electroconvulsive Therapy, Hypertensive Surge, Blood-Brain Barrier Breach, and Amnesia
  16. Searching for the Mechanism(s) of ECT’s Therapeutic Effect
  17. A Primer for the Conceptualization of the Mechanism of Action of Electroconvulsive Therapy, 1: Defining the Question
  18. Cardiovascular adverse effects of newer antidepressants
  19. Potentially Significant Versus Clinically Significant Drug Interactions: Pomegranate Juice as a Case in Point
  20. Antidepressants and Testicular Cancer: Cause Versus Association
  21. Selective Serotonin Reuptake Inhibitor Drug Interactions in Patients Receiving Statins
  22. Bilateral peripheral edema as a rare adverse effect of escitalopram
  23. Moving psychopharmacological drug development to the developing world
  24. Dancing mind - Promoting mental health through the medium of movement
  25. Rapid, illegible handwriting as a symptom of obsessive-compulsive disorder
  26. Policy of the Indian Journal of Psychiatry on the problem of plagiarism
  27. Unilateral galactorrhea associated with low-dose escitalopram
  28. Augmenting Selective Serotonin Reuptake Inhibitors With Clomipramine in Obsessive-Compulsive Disorder: Benefits and Risks
  29. Reversible abnormality of the splenium in a bipolar patient with neuroleptic malignant syndrome
  30. Transcranial Direct Current Stimulation for Refractory Auditory Hallucinations in Schizophrenia
  31. Learning From History: How to Swallow a Pill
  32. Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins
  33. Famotidine Augmentation in Schizophrenia: Hope or Hype?
  34. Antidepressant Use in Pregnancy and Risk of Autism Spectrum Disorders: A Critical Examination of the Evidence
  35. Electroconvulsive Therapy Attenuates Dendritic Arborization in the Basolateral Amygdala
  36. Once- to Twice-Daily, 3-Year Domiciliary Maintenance Transcranial Direct Current Stimulation for Severe, Disabling, Clozapine-Refractory Continuous Auditory Hallucinations in Schizophrenia
  37. Levothyroxine in Psychiatry
  38. Antenatal Exposure to Selective Serotonin Reuptake Inhibitors and Duration of Gestation
  39. Low-Dose Amisulpride and Elevation in Serum Prolactin
  40. Signal-to-Noise Ratio, Variability, and Their Relevance in Clinical Trials
  41. Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure
  42. Antidepressant Action of Atypical Antipsychotics
  43. Augmentation of Venlafaxine With Bupropion
  44. Drug Interactions in the Treatment of Depression in Patients Receiving β-Blocker Drugs
  45. Prolonged, self-administration of ultra-high doses of quetiapine
  46. Screening for disease, psychological testing, and psychotherapy Looking behind the mirror
  47. Ejaculatory dysfunction associated with low dose amisulpride
  48. Anesthesiological training and certification for psychiatrists practising unmodified ECT
  49. Ethical issues in psychiatry research: Special concerns for India
  50. How to read a research paper: Ecological validity, apples, and oranges
  51. Ventricular premature contractions associated with iloperidone
  52. Images in electroconvulsive therapy: Pilot impressions suggesting that ECT reduces excitatory synapses in the basolateral amygdala
  53. Drug Interactions in the Treatment of Depression in Patients With Ischemic Heart Disease
  54. Serotonin Reuptake Inhibitor Treatment of Obsessive-Compulsive Symptoms in Clozapine-Medicated Schizophrenia
  55. Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study
  56. There’s More to Placebo-Related Improvement Than the Placebo Effect Alone
  57. Antipsychotic Drugs and Myocardial Infarction in Patients With Dementia
  58. Age, Statin Use, and the Risk for Incident Parkinson Disease
  59. Hyperactive sexual desire in Klinefelter Syndrome: Treatment with sertraline
  60. Breast Cancer and Antidepressant Use
  61. Is Sitting Harmful to Health? It Is Too Early to Say
  62. Modafinil and Armodafinil in Schizophrenia
  63. Do Angiotensin Receptor Blockers Really Hold Promise for the Improvement of Cognitive Functioning?
  64. Drugs That Escape Hepatic Metabolism
  65. Schizophrenia and Smoking
  66. Black Tea and Blood Pressure: Did the Blood Pressure Fall or Rise?
  67. Decreasing Adverse Outcomes Associated With Unmodified ECT
  68. Electrical Parameters and the Efficacy of ECT
  69. Maintenance ECT as a Therapeutic Approach to Medication-Refractory Epilepsy in an Adult With Mental Retardation
  70. Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn
  71. Continuation of ECT After Recovery From Transient, ECT-Induced, Postictal Cortical Blindness
  72. Emergence of psychotic symptoms during Internet withdrawal
  73. Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder
  74. Suicide: An Indian perspective
  75. Psychopharmacology of schizophrenia: The future looks bleak
  76. Behavioral interventions for insomnia: Theory and practice
  77. Covert medication: Do means justify the ends?
  78. Investigation of the possible role of Shankapushpi in the attenuation of ECT induced amnestic deficits
  79. Position statement and guidelines on unmodified electroconvulsive therapy
  80. Electroconvulsive Therapy for Posttraumatic Stress Disorder
  81. Odd Odds
  82. Administration of a selective glucocorticoid antagonist attenuates electroconvulsive shock-induced retrograde amnesia
  83. Electroconvulsive Therapy
  84. Standard operating procedures for clinical practice
  85. Lorazepam-induced prolonged apnea after ECT-induced prolonged seizure
  86. Prayer, randomized controlled trials and distance healing: A response to Dr. Jana
  87. Exploring new frontiers in neuropsychopharmacology: SSRIs for stroke
  88. How to read a research paper: Reading between and beyond the lines
  89. The MMR vaccine and autism: Sensation, refutation, retraction, and fraud
  90. How to write a good abstract for a scientific paper or conference presentation
  91. Placeboxetine for major depressive disorder: Researcher, author, reader, and reviewer perspectives on randomized controlled trials
  92. Development of a murine animal model of depression for repeated dosing with human interferon alpha
  93. A 6-week, multicentre, randomized controlled clinical trial to evaluate the safety and efficacy of placeboxetine hydrochloride in the treatment of major depressive disorder in an Indian setting
  94. Serotonin Reuptake Inhibitor Antidepressants and Abnormal Bleeding
  95. Electroconvulsive Therapy in a Patient With Klippel-Trenaunay-Weber Syndrome Complicated by Partial Popliteal Vein Thrombosis
  96. Uneventful use of haloperidol and trihehexyphenidyl during three consecutive pregnancies
  97. Variations on a Theme of Unmodified Electroconvulsive Therapy
  98. The Depiction of Electroconvulsive Therapy in Hindi Cinema
  99. The Safety and Efficacy of Benzodiazepine-Modified Treatments as a Special Form of Unmodified ECT
  100. A Survey of the Practice of Electroconvulsive Therapy in Asia
  101. The Practice of Electroconvulsive Therapy in Asia
  102. Continuing medical education: SSRIs and pregnancy
  103. Primary prevention for offspring of parents with mental illness
  104. Dose calculation with brief-pulse ECT demystified
  105. Innovative approaches to treatment - refractory depression: The ketamine story
  106. Prayer, randomized controlled trials and healing: A response to Prof. Abraham Verghese
  107. Stahl′s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
  108. Efficacy of ECT in Chronic, Severe, Antidepressant- and CBT-Refractory PTSD: An Open, Prospective Study
  109. The evolution of Indian psychiatric research: An examination of the early decades of the Indian journal of Psychiatry
  110. Lithium, trifluperazine and idiopathic leucopenia: Author and reviewer perspectives on how to write a good case report
  111. How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy
  112. Familial vulnerability to an unusual cognitive adverse effect of topiramate: Discussion of mechanisms
  113. Maintenance Electroconvulsive Therapy
  114. Desvenlafaxine
  115. Depression and schizophrenia
  116. Postgraduate corner: Continuing medical education: Psychopharmacology
  117. Teratogenicity and hyperprolactinemia
  118. Prayer and healing: A medical and scientific perspective on randomized controlled trials
  119. Ashwagandha for anxiety disorders
  120. Melatonin treatment of shoulder-and-neck dyskinesia possibly related to fluoxetine treatment
  121. Systematic enhancement of functioning as a therapeutic technique in conversion disorder
  122. Leukopenia and thrombocytopenia on adding aripiprazole to phenytoin
  123. The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments
  124. Celecoxib as an in vivo probe of cyclooxygenase-2 mechanisms underlying retrograde amnesia in an animal model of ECT
  125. The Ebbinghaus retention curve: training does not increase the ability to apply pressure immobilisation in simulated snake bite—implications for snake bite first aid in the developing world
  126. Successful use of maintenance rTMS for 8 months in a patient with antipsychotic-refractory auditory hallucinations
  127. Pharmacological Attenuation of Electroconvulsive Therapy-Induced Cognitive Deficits
  128. Continuing medical education
  129. Postgraduate corner: Continuing medical education
  130. The National Institute of Open Schooling
  131. Post-graduate CME
  132. Schizophrenia, Osteoporosis, and an Examination of the Risk of Fractures in Patients Receiving ECT
  133. Unilateral Nondominant Electrode Placement as a Risk Factor for Recall of Awareness Under Anesthesia During Electroconvulsive Therapy
  134. First- vs Second-Generation Antipsychotic Drugs in Schizophrenia
  135. The Influence of Name on the Acceptability of ECT
  136. Safety of Repeated Courses of Electroconvulsive Therapy in a Patient With Harrington Rods
  137. ECT Practice in Asia
  138. Melatonin in Schizophrenic Outpatients With Insomnia
  139. Confounding
  140. Glucocorticoid mechanisms may contribute to ECT-induced retrograde amnesia
  141. Electroconvulsive Therapy in India
  142. Cortical Blindness Associated With Electroconvulsive Therapy
  143. Aripiprazole use in a pregnant schizoaffective woman
  144. Simultaneous True Seizures and Pseudoseizures
  145. ECT for Treatment-Resistant Schizophrenia
  146. Sore throat and obsessions: A causal link?
  147. Anti-amnestic properties of Brahmi and Mandookaparni in a rat model
  148. The case for humour: Moving one step further
  149. Controversy revisited: selective serotonin reuptake inhibitors in paediatric depression
  150. ECT Devices in India
  151. Knowledge About and Attitudes Towards ECT: Methodological Issues
  152. Why Some Psychiatrists May Be Unwilling To Receive Electroconvulsive Therapy
  153. Australasian commentary on CANMAT guidelines for treatment of bipolar disorder
  154. In Vigorous Defense of Whole Brain Kindling and a Reconsideration on Naming the Phenomenon
  155. The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research
  156. Tumor Necrosis Factor-Alpha, Depression, and ECT: Toward a Better Understanding of the Relationships
  157. Possible Impact of Dropout in a Study of High-Dose Olanzapine and Prolactin Levels
  158. Antidepressant-Withdrawal Mania
  159. Multiple Expansion Disorder
  160. Spectral EEG Effects of Electroconvulsive Shock Stimulus Parameters
  161. The Dilemma of Unmodified Electroconvulsive Therapy
  162. Need for Homogeneity of Diagnosis in Studies on the Cognitive Effects of ECT
  163. Does Absolute Charge Administered Predict Speed of Response to Right Unilateral ECT?
  164. Confirmation of Whole-Brain Kindling With Repeated Subthreshold Electroconvulsive Shocks: A Controlled Study
  165. ECS Seizure Threshold: Normal Variations, and Kindling Effects of Subconvulsive Stimuli
  166. Pharmacological Treatment of Severe Psychiatric Disorders in the Developing World
  167. ECT in the management of major depression: Implications of recent research
  168. Effect of Stimulus Intensity and Number of Treatments on ECS-Related Seizure Duration and Retrograde Amnesia in Rats
  169. Continuation and Maintenance ECT: A Review of Recent Research
  170. ECT in Poetry: In a Lighter Vein
  171. Effects of Pulse Amplitude, Pulse Frequency, and Stimulus Duration on Seizure Threshold: A Laboratory Investigation
  172. Zolpidem, vascular headache, and hallucinations in an adolescent
  173. High But Not Low ECS Stimulus Intensity Augments Apomorphine-Stimulated Dopamine Postsynaptic Receptor Functioning in Rats
  174. Memory protective effect of indomethacin against electroconvulsive shock-induced retrograde amnesia in rats
  175. Effects of Stimulus Parameters on Seizure Duration and ECS-Induced Retrograde Amnesia
  176. GS-02 for Dysthymic Disorder
  177. GS-02 for Dysthymic Disorder
  178. Phenylephrine and ECS-Induced Retrograde Amnesia
  179. Effect of innate direction bias on T-maze learning in rats: implications for research
  180. Confusion and dysphoria with low‐dose topiramate in a patient with bipolar disorder
  181. A Preliminary Survey of Rhinotillexomania in an Adolescent Sample
  182. Quantifying the ECT Dose: The Right Unit Remains Elusive
  183. Nitroprusside and ECS-Induced Retrograde Amnesia
  184. Melatonin in Medically Ill Patients With Insomnia
  185. Electroconvulsive Therapy and the Alpha-2 Noradrenergic Receptor: Implications of Treatment Schedule Effects
  186. Herbal Treatments for ECS-Induced Memory Deficits: A Review of Research and a Discussion on Animal Models
  187. A Simplified Herbal Formulation Attenuates Electroconvulsive Shock-Induced Anterograde Amnesia
  188. Reply to "Obsessive-Compulsive Symptoms With Risperidone"
  189. Duration of Liquid Fast Before ECT
  190. Attenuation of ECS-Induced Retrograde Amnesia by Using an Herbal Formulation
  191. Risperidone May Worsen Fluoxetine-Treated OCD
  192. Is alternate‐day lithium really ineffective?
  193. AgNORs and their relationship to cell size, histological grade, lymph node involvement, metastases, and survival pattern in carcinoma of the breast: A study from south India
  194. BR-16A restricts development of electroconvulsive shock-induced retrograde amnesia
  195. BR-16A protects against ECS-induced anterograde amnesia
  196. Naltrexone and Alcohol Dependence: Some Methodological Issues
  197. Not significantly different is not the same as significantly similar